Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

What is the current role of intracavernosal injection in management of erectile dysfunction?

International Journal of Impotence Research volume 28, pages 88–95 (2016)Cite this article

Subjects

Abstract

The emerging of intracavernosal injection (ICI) of vasoactive materials was a major breakthrough in the treatment of erectile dysfunction (ED). However, the current state and future direction of ICI role in the armamentarium of diagnosis, prevention and treatment of ED are not well defined. The aim of this study was to address the current place of ICI in the armamentarium of ED diagnosis and treatment. An English-language MEDLINE review for the utilization of 'intracavernosal injection & erectile dysfunction' was performed from 1990 to present time. Four hundred forty-eight articles were analyzed and classified according to the current utilization of ICI in the following conditions; diagnosis of ED, phosphodiesterase-5 inhibitor (PDE5I) non-responders, diabetes, post radical prostatectomy (RP), stem cells and gene therapy, new intracavernosal drugs, adverse effects and couple satisfaction. This paper is not a standard systematic review; it is eventually a literature review of original peer-reviewed manuscripts and clinical trials reported in Medline. The comprehensive analyses of all the reviewed data were not possible as the level of evidence for utility of ICI in each topic was not available. Current date have established the role of ICI of vasoactive materials as a very common alternative domain in treatment of severe ED particularly in diabetic patients, post-RP, PDE5I non-responders. Further, new studies have denoted the potential future role of intracavernosal treatment for ED in the era of stem cells and gene therapy. ICI of vasoactive material continues to be a highly effective and safe treatment tool for men with wide varieties of ED etiologies. Several experimental and clinical studies are currently investigating new ICI materials. Hopefully in the near future, we might witness evolved molecules and innovative strategies that could help to treat ED patients with different etiologies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J . Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 2006; 20: 429–435.

    Google Scholar 

  2. Virag R . Intracavernous injection of papaverine for erectile failure. Lancet 1982; 2: 938.

    CAS  PubMed  Google Scholar 

  3. Shmueli J, Israilov S, Segenreich E, Baniel J, Livne P . Progressive treatment of erectile dysfunction with intracorporeal injections of different combinations of vasoactive agents. Int J Impot Res 1999; 11: 15–19.

    CAS  PubMed  Google Scholar 

  4. Baniel J, Israilov S, Engelstein D, Shmueli J, Segenreich E, Livne PM . Three-year outcome of a progressive treatment program for erectile dysfunction with intracavernous injections of vasoactive drugs. Urology 2000; 56: 647–652.

    CAS  PubMed  Google Scholar 

  5. Vaidyanathan S, Soni BM, Krishnan KR . Special precautions to be observed while using alprostadil in patients with spinal cord injury. Spinal Cord 1997; 35: 402–403.

    CAS  PubMed  Google Scholar 

  6. Purvis K, Brekke I, Christiansen E . Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure. Int J Impot Res 1996; 8: 9–16.

    CAS  PubMed  Google Scholar 

  7. Dhir RR, Lin HC, Canfield SE, Wang R . Combination therapy for erectile dysfunction: an update review. Asian J Androl 2011; 13: 382–390.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Mulhall JP, Morgentaler A . Penile rehabilitation should become the norm for radical prostatectomy patients. J Sex Med 2007; 4: 538–543.

    PubMed  Google Scholar 

  9. Burnett AL . Erectile dysfunction following radical prostatectomy. JAMA 2005; 293: 2648–2653.

    Article  CAS  PubMed  Google Scholar 

  10. Bancroft J, Gutierrez P . Erectile dysfunction in men with and without diabetes mellitus: a comparative study. Diabetic Med 1996; 13: 84–89.

    CAS  PubMed  Google Scholar 

  11. Raina R, Nandipati KC, Agarwal A, Mansour D, Kaelber DC, Zippe CD . Combination therapy: medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy. J Androl 2005; 26: 757–760.

    CAS  PubMed  Google Scholar 

  12. Viswaroop B, B A, Gopalakrishnan G . Evaluating erectile dysfunction: oral sildenafil versus intracavernosal injection of papaverine. Natl Med J India 2005; 18: 299–301.

    PubMed  Google Scholar 

  13. Yang Y, Hu JL, Ma Y, Wang HX, Chen Z, Xia JG et al. Pharmaco-induced erections for penile color-duplex ultrasound: oral PDE5 inhibitors or intracavernosal injection? Int J Impot Res 2012; 24: 191–195.

    CAS  PubMed  Google Scholar 

  14. Park JK, Park JS, Jeon SB, Cui WS, Kim SZ, Kang KK et al. Why a combined intracavernosal injection with trimix and oral sildenafil is reliable therapy in the ultrasonographic evaluation of erectile dysfunction. BJU Int 2008; 102: 993–997.

    PubMed  Google Scholar 

  15. Ghafoori M, Hoseini K, Shakiba M . Comparison of one-side and bilateral intracavernosal papaverine injection on a Doppler study of the penis. Int J Impot Res 2009; 21: 382–386.

    CAS  PubMed  Google Scholar 

  16. Arafa M, Eid H, Shamloul R . Significance of phentolamine redosing during prostaglandin E1 penile color Doppler ultrasonography in diagnosis of vascular erectile dysfunction. Int J Urol 2007; 14: 476–477.

    PubMed  Google Scholar 

  17. Ellsworth P, Kirshenbaum EM . Current concepts in the evaluation and management of erectile dysfunction. Urol Nurs 2008; 28: 357–369.

    PubMed  Google Scholar 

  18. Fink HA, Mac Donald R, Rutks IR, Nelson DB, Wilt TJ . Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002; 162: 1349–1360.

    CAS  PubMed  Google Scholar 

  19. El-Sakka AI, Anis T, Khadr N, Ismail TA, Hegazy AM, Fekry O et al. Sildenafil treatment of erectile dysfunction in the Middle East: an observational analysis of patients with diabetes and/or hypertension treated in the clinical practice setting. J Int Med Res 2011; 39: 558–568.

    CAS  PubMed  Google Scholar 

  20. El-Sakka AI . Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. Eur Urol 46: 503–509 2004.

    CAS  PubMed  Google Scholar 

  21. Kendirci M, Tanriverdi O, Trost L, Hellstrom WJ . Management of sildenafil treatment failures. Curr Opin Urol 2006; 16: 449–459.

    PubMed  Google Scholar 

  22. Sivalingam S, Hashim H, Schwaibold H . An overview of the diagnosis and treatment of erectile dysfunction. Drugs 2006; 66: 2339–2355.

    CAS  PubMed  Google Scholar 

  23. Brant WO, Bella AJ, Lue TF . Treatment options for erectile dysfunction. Endocrinol Metab Clin North Am 2007; 36: 465–479.

    CAS  PubMed  Google Scholar 

  24. Montorsi F, Salonia A, Zanoni M, Pompa P, Cestari A, Guazzoni G et al. Current status of local penile therapy. Int J Impot Res 2002; 14 (Suppl 1): S70–S81.

    PubMed  Google Scholar 

  25. Urciuoli R, Cantisani TA, Carlini M, Giuglietti M, Botti FM et al. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev 2004; 2: Art. No. CD001784.

  26. El-Sakka AI . Intracavernosal prostaglandin E1 self versus office injection therapy in patients with erectile dysfunction. Int J Impot Res 2006; 18: 180–185.

    CAS  PubMed  Google Scholar 

  27. Zargooshi J . Male sexual dysfunction in unconsummated marriage: long-term outcome in 417 patients. J Sex Med 2008; 5: 2895–2903.

    PubMed  Google Scholar 

  28. Guay AT . Sexual dysfunction in the diabetic patient. Int J Impot Res 2001; 13: S47–S50.

    PubMed  Google Scholar 

  29. El-Sakka AI, Tayeb KA . Erectile dysfunction risk factors in non-insulin dependent diabetic Saudi patients. J Urol 2003; 169: 1043–1047.

    Article  PubMed  Google Scholar 

  30. El-Sakka AI . Association of risk factors and medical co-morbidities with male sexual dysfunctions. J Sexual Med 2007; 4: 1691–1700.

    Google Scholar 

  31. Stuckey BG, Jadzinsky MN, Murphy LJ, Montorsi F, Kadioglu A, Fraige F et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003; 26: 279–284.

    CAS  PubMed  Google Scholar 

  32. Kolluru GK, Bir SC, Kevil CG . Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med 2012; 2012: 918267.

    PubMed  PubMed Central  Google Scholar 

  33. Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G . Diabetic impotence treated by intracavernosal injections: high treatment compliance and increasing dosage of vaso-active drugs. Eur Urol 2001; 40: 398–403.

    CAS  PubMed  Google Scholar 

  34. Althof SE, Turner LA, Levine SB, Risen C, Kursh E, Bodner D et al. Why do so many people drop out from auto-injection therapy for impotence? J Sex Marital Ther 1989; 15: 121–129.

    CAS  PubMed  Google Scholar 

  35. Perimenis P, Konstantinopoulos A, Perimeni PP, Gyftopoulos K, Kartsanis G, Liatsikos E et al. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J Androl 2006; 8: 219–224.

    CAS  PubMed  Google Scholar 

  36. Perimenis P, Athanasopoulos A, Geramoutsos I, Barbalias G . The incidence of pharmacologically induced priapism in the diagnostic and therapeutic management of 685 men with erectile dysfunction. Urol Int 2001; 66: 22–26.

    Google Scholar 

  37. Perimenis P, Markou S, Gyftopoulos K, Athanasopoulos A, Giannitsas K, Barbalias G . Switching from long-term treatment with self-injections to oral sildenafil in diabetic patients with severe erectile dysfunction. Eur Urol 2002; 41: 387–391.

    CAS  PubMed  Google Scholar 

  38. Liu G, Sun X, Bian J, Wu R, Guan X, Ouyang B et al. Correction of diabetic erectile dysfunction with adipose derived stem cells modified with the vascular endothelial growth factor gene in a rodent diabetic model. PLoS One 2013; 8: e72790.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Soni SD, Song W, West JL, Khera M . Nitric oxide-releasing polymeric microspheres improve diabetes-related erectile dysfunction. J Sex Med 2013; 10: 1915–1925.

    CAS  PubMed  Google Scholar 

  40. Kim SO, Lee HS, Ahn K, Park K . COMP-angiopoietin-1 promotes cavernous angiogenesis in a type 2 diabetic rat model. J Korean Med Sci 2013; 28: 725–730.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Yang Z, Zhou Z, Wang X, Peng M, Zhou H, Meng Z et al. Short hairpin ribonucleic acid constructs targeting insulin-like growth factor binding protein-3 ameliorates diabetes mellitus-related erectile dysfunction in rats. Urology 2013; 81: e11–e16.

    Google Scholar 

  42. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225–249.

    PubMed  Google Scholar 

  43. Arai Y, Okubo K, Aoki Y, Maekawa S, Okada T, Maeda H et al. Patient-reported quality of life after radical prostatectomy for prostate cancer. Int J Urol 1999; 6: 78–86.

    CAS  PubMed  Google Scholar 

  44. Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM . Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality of life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1999; 54: 503–508.

    CAS  PubMed  Google Scholar 

  45. Rogers CG, Trock BP, Walsh PC . Preservation of accessory pudendal arteries during radical retropubic prostatectomy: Surgical technique and results. Urology 2004; 64: 148–151.

    PubMed  Google Scholar 

  46. Leungwattanakij S, Bivalacqua TJ, Usta MF, Yang DY, Hyun JS, Champion HC et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 2003; 24: 239–245.

    PubMed  Google Scholar 

  47. User HM, Hairston JH, Zelner DJ, McKenna KE, McVary KT . Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol 2003; 169: 1175–1179.

    PubMed  Google Scholar 

  48. Tal R, Heck M, Teloken P, Siegrist T, Nelson CJ, Mulhall JP . Peyronie’s disease following radical prostatectomy: incidence and predictors. J Sex Med 2010; 7: 1254–1261.

    PubMed  Google Scholar 

  49. Vignozzi L, Filippi S, Morelli A, Marini M, Chavalmane A, Fibbi B et al. Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism. J Sex Med 2009; 6: 1270–1283.

    CAS  PubMed  Google Scholar 

  50. Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997; 158: 1408–1410.

    CAS  PubMed  Google Scholar 

  51. Nandipati K, Raina R, Agarwal A, Zippe CD . Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res 2006; 18: 446–451.

    CAS  PubMed  Google Scholar 

  52. Claro Jde A, de Aboim JE, Maríngolo M, Andrade E, Aguiar W, Nogueira M et al. Intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: an observational study. Sao Paulo Med J 2001; 119: 135–137.

    PubMed  Google Scholar 

  53. Raina R, Lakin MM, Thukral M, Agarwal A, Ausmundson S, Montague DK et al. Long term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res 2003; 15: 318–322.

    CAS  PubMed  Google Scholar 

  54. Mydlo JH, Viterbo R, Crispen P . Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. BJU Int 2005; 95: 843–846.

    CAS  PubMed  Google Scholar 

  55. Jung AR, Choi YS, Piao S, Park YH, Shrestha KR, Jeon SH et al. The effect of PnTx2-6 protein from Phoneutria nigriventer spider toxin on improvement of erectile dysfunction in a rat model of cavernous nerve injury. Urology 2014; 84: e9–e17.

    Google Scholar 

  56. Lasker GF, Pankey EA, Frink TJ, Zeitzer JR, Walter KA, Kadowitz PJ . The sGC activator BAY 60-2770 has potent erectile activity in the rat. Am J Physiol Heart Circ Physiol 2013; 304: H1670–H1679.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Lin H, Yuan J, Ruan KH, Yang W, Zhang J, Dai Y et al. COX-2-10aa-PGIS gene therapy improves erectile function in rats after cavernous nerve injury. J Sex Med 2013; 10: 1476–1487.

    CAS  PubMed  Google Scholar 

  58. You D, Jang MJ, Lee J, Jeong IG, Kim HS, Moon KH et al. Periprostatic implantation of human bone marrow-derived mesenchymal stem cells potentiates recovery of erectile function by intracavernosal injection in a rat model of cavernous nerve injury. Urology 2013; 81: 104–110.

    PubMed  Google Scholar 

  59. You D, Jang MJ, Lee J, Suh N, Jeong IG, Sohn DW et al. Comparative analysis of periprostatic implantation and intracavernosal injection of human adipose tissue-derived stem cells for erectile function recovery in a rat model of cavernous nerve injury. Prostate 2013; 73: 278–286.

    CAS  PubMed  Google Scholar 

  60. Domes T, Chung E, DeYoung L, MacLean N, Al-Shaiji T, Brock G . Clinical outcomes of intracavernosal injection in postprostatectomy patients: a single-center experience. Urology 2012; 79: 150–155.

    PubMed  Google Scholar 

  61. Mosbah A, El Bahnasawy M, Osman Y, Hekal IA, Abou-Beih E, Shaaban A . Early versus late rehabilitation of erectile function after nerve-sparing radical cystoprostatectomy: a prospective randomized study. J Sex Med 2011; 8: 2106–2111.

    PubMed  Google Scholar 

  62. Teloken P, Mesquita G, Montorsi F, Mulhall J . Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners. J Sex Med 2009; 6: 2032–2038.

    PubMed  Google Scholar 

  63. Bach AD, Bannasch H, Galla TJ, Bittner KM, Stark GB . Fibrin glue as matrix for cultured autologous urothelial cells in urethral reconstruction. Tissue Eng 2001; 7: 45–53.

    CAS  PubMed  Google Scholar 

  64. Fraser M, Thomas DF, Pitt E, Harnden P, Trejdosiewicz LK, Southgate J . A surgical model of composite cystoplasty with cultured urothelial cells: a controlled study of gross outcome and urothelial phenotype. BJU Int 2004; 93: 609–616.

    CAS  PubMed  Google Scholar 

  65. Matsunuma H, Kagami H, Narita Y, Hata K, Ono Y, Ohshima S et al. Constructing a tissue-engineered ureter using a decellularized matrix with cultured uroepithelial cells and bone marrow derived mononuclear cells. Tissue Eng 2006; 12: 509–518.

    CAS  PubMed  Google Scholar 

  66. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012; 7: e47559.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Qiu X, Lin H, Wang Y, Yu W, Chen Y, Wang R et al. Intracavernous transplantation of bone marrow-derived mesenchymal stem cells restores erectile function of streptozocin-induced diabetic rats. J Sex Med 2011; 8: 427–436.

    PubMed  Google Scholar 

  68. Qiu X, Sun C, Yu W, Lin H, Sun Z, Chen Y et al. Combined strategy of mesenchymal stem cells injection with VEGF gene therapy for the treatment of diabetes associated erectile dysfunction. J Androl 2012; 33: 37–44.

    CAS  PubMed  Google Scholar 

  69. Gou X, He WY, Xiao MZ, Qiu M, Wang M, Deng YZ et al. Transplantation of endothelial progenitor cells transfected with VEGF165 to restore erectile function in diabetic rats. Asian J Androl 2011; 13: 332–338.

    CAS  PubMed  Google Scholar 

  70. Garcia MM, Fandel TM, Lin G, Shindel AW, Banie L, Lin CS et al. Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue derived stem cells. J Sex Med 2010; 7: 89–98.

    PubMed  PubMed Central  Google Scholar 

  71. Bahk JY, Jung JH, Han H, Min SK, Lee YS . Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant 2010; 8: 150–160.

    PubMed  Google Scholar 

  72. Wu S, Wang Z, Bharadwaj S, Hodges SJ, Atala A, Zhang Y . Implantation of autologous urine derived stem cells expressing vascular endothelial growth factor for potential use in genitourinary reconstruction. J Urol 2011; 186: 640–647.

    CAS  PubMed  Google Scholar 

  73. Ouyang B, Sun X, Han D, Chen S, Yao B, Gao Y et al. Human urine-derived stem cells alone or genetically-modified with FGF2 improve type 2 diabetic erectile dysfunction in a rat model. PLoS ONE 2014; 9: e92825.

    PubMed  PubMed Central  Google Scholar 

  74. Bahramsoltani M, De Spiegelaere W, Janczyk P, Hiebl B, Cornillie P, Plendl J . Quantitation of angiogenesis in vitro induced by VEGF-A and FGF-2 in two different human endothelial cultures - an all-in-one assay. Clin Hemorheol Microcirc 2010; 46: 189–202.

    PubMed  Google Scholar 

  75. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K et al. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 2002; 90: 966–973.

    CAS  PubMed  Google Scholar 

  76. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003; 9: 604–613.

    CAS  PubMed  Google Scholar 

  77. Byrne RR, Henry GD, Rao DS, Huynh TT, Pippen AM, Annex BH et al. Vascular endothelial growth factor restores corporeal smooth muscle function in vitro. J Urol 2001; 165: 1310–1315.

    CAS  PubMed  Google Scholar 

  78. Lee MC, El-Sakka AI, Graziottin TM, Ho HC, Lin CS, Lue TF et al. The effect of vascular endothelial growth factor on a rat model of traumatic arteriogenic erectile dysfunction. J Urol 2002; 167: 761–767.

    CAS  PubMed  Google Scholar 

  79. Bivalacqua TJ, Deng W, Kendirci M, Usta MF, Robinson C, Taylor BK et al. Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age associated erectile dysfunction. Am J Physiol Heart Circ Physiol 2007; 292: H1278–H1290.

    CAS  PubMed  Google Scholar 

  80. Cao B, Huard J . Muscle-derived stem cells. Cell Cycle 2004; 3: 104–107.

    CAS  PubMed  Google Scholar 

  81. Choi A, Kim SD, Sohn DW, Kim DB, Kim HW, Cho SY et al. The effect of human umbilical cord blood derived mesenchymal stem cell therapy in rat model of cavernosal nerve injury. Korean J Androl 2008; 26: 136–141.

    Google Scholar 

  82. Woo JC, Bae WJ, Kim SJ, Kim SD, Sohn DW, Hong SH et al. Transplantation of muscle-derived stem cells into the corpus cavernosum restores erectile function in a rat model of cavernous nerve injury. Korean J Urol 2011; 52: 359–363.

    PubMed  PubMed Central  Google Scholar 

  83. Mangir N, Akbal C, Tarcan T, Simsek F, Turkeri L . Mesenchymal stem cell therapy in treatment of erectile dysfunction: autologous or allogeneic cell sources? Int J Urol 2014; 21: 1280–1285.

    PubMed  Google Scholar 

  84. Yilmaz D, Bayatli N, Un O, Kadowitz PJ, Sikka SC, Gur S . The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction. Urology 2014; 83: e7–e12.

    Google Scholar 

  85. da Costa Gonçalves AC, Fraga-Silva RA, Leite R, Santos RA . AVE 0991, a non-peptide Mas-receptor agonist, facilitates penile erection. Exp Physiol 2013; 98: 850–855.

    PubMed  Google Scholar 

  86. Lasker GF, Pankey EA, Allain AV, Dhaliwal JS, Stasch JP, Murthy SN et al. Analysis of erectile responses to BAY 41-8543 and muscarinic receptor stimulation in the rat. J Sex Med 2013; 10: 704–718.

    CAS  PubMed  Google Scholar 

  87. Nunes KP, Costa-Gonçalves A, Lanza LF, Cortes SF, Cordeiro MN, Richardson M et al. Tx2-6 toxin of the Phoneutria nigriventer spider potentiates rat erectile function. Toxicon 2008; 51: 1197–1206.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Nunes KP, Toque HA, Borges MH, Richardson M, Webb RC, de Lima ME . Erectile function is improved in aged rats by PnTx2-6, a toxin from Phoneutria nigriventer spider venom. J Sex Med 2012; 9: 2574–2581.

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Xie D, Pippen AM, Odronic SI, Annex BH, Donatucci CF . Intracavernosal basic fibroblast growth factor improves vasoreactivity in the hypercholesterolemic rabbit. J Sex Med 2006; 3: 223–232.

    CAS  PubMed  Google Scholar 

  90. Park K, Ahn KY, Kim MK, Lee SE, Kang TW, Ryu SB . Intracavernosal injection of vascular endothelial growth factor improves erectile function in aged rats. Eur Urol 2004; 46: 403–407.

    CAS  PubMed  Google Scholar 

  91. Gou X, He WY, Xiao MZ, Qiu M, Wang M, Deng YZ et al. Transplantation of endothelial progenitor cells transfected with VEGF165 to restore erectile function in diabetic rats. Asian J Androl 2011; 13: 332–338.

    CAS  PubMed  Google Scholar 

  92. Lasker GF, Matt CJ, Badejo AM Jr, Casey DB, Dhaliwal JS, Murthy SN et al. Intracavernosal administration of sodium nitrite as an erectile pharmacotherapy. Can J Physiol Pharmacol 2010; 88: 770–776.

    CAS  PubMed  Google Scholar 

  93. Sung HH, Ahn JS, Kim JJ, Choo SH, Han DH, Lee SW . The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors. Andrology 2014; 2: 45–50.

    CAS  PubMed  Google Scholar 

  94. Nelson CJ, Hsiao W, Balk E, Narus J, Tal R, Bennett NE et al. Injection anxiety and pain in men using intracavernosal injection therapy after radical pelvicsurgery. J Sex Med 2013; 10: 2559–2565.

    PubMed  Google Scholar 

  95. Hsiao W, Bennett N, Guhring P, Narus J, Mulhall JP . Satisfaction profiles in men using intracavernosal injection therapy. J Sex Med 2011; 8: 512–517.

    PubMed  Google Scholar 

  96. Mulhall JP, Simmons J . Assessment of comparative treatment satisfaction with sildenafil citrate and penile injection therapy in patients responding to both. BJU Int 2007; 100: 1313–1316.

    PubMed  Google Scholar 

  97. Kim SC, Chang IH, Jeon HJ . Preference for oral sildenafil or intracavernosal injection in patients with erectile dysfunction already using intracavernosal injection for >1 year. BJU Int 2003; 92: 277–280.

    CAS  PubMed  Google Scholar 

  98. El-Sakka AI, Yassin AA . Amelioration of penile fibrosis: myth or reality. J Androl 2010; 31: 324–335.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

    A I El-Sakka

Authors
  1. A I El-Sakka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A I El-Sakka.

Ethics declarations

Competing interests

The author declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El-Sakka, A. What is the current role of intracavernosal injection in management of erectile dysfunction?. Int J Impot Res 28, 88–95 (2016). https://doi.org/10.1038/ijir.2016.14

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2016.14

This article is cited by

Search

Advanced search

Quick links